Literature DB >> 7247389

Susceptibility of multiply antibiotic-resistant pneumococci to the new beta-lactam drugs and rosaramicin.

S H Landesman1, M Cummings, A Gruarin, H Bernheimer.   

Abstract

Eight new beta-lactam antibiotics and rosaramicin were tested for their activity against penicillin-susceptible and multiply resistant pneumococci. All of the beta-lactam drugs were 50- to 150-fold less active against the drug-resistant pneumococci when compared with their activity against penicillin-susceptible pneumococci. Rosaramicin activity was similar to that of erythromycin.

Entities:  

Mesh：

Substances：

Year:  1981        PMID： 7247389      PMCID： PMC181500          DOI： 10.1128/AAC.19.4.675

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  2 in total

1.  Emergence of multiply resistant pneumococci.

Authors:  M R Jacobs; H J Koornhof; R M Robins-Browne; C M Stevenson; Z A Vermaak; I Freiman; G B Miller; M A Witcomb; M Isaäcson; J I Ward; R Austrian
Journal:  N Engl J Med       Date:  1978-10-05       Impact factor: 91.245

2.  Diffusion of a new beta-lactam (LY 127935) into cerebrospinal fluid. Implications for therapy of gram-negative bacillary meningitis.

Authors:  S H Landesman; M L Corrado; C C Cherubin; M Gombert; D Cleri
Journal:  Am J Med       Date:  1980-07       Impact factor: 4.965
  2 in total
  8 in total

Review 1.  World-wide development of antibiotic resistance in pneumococci.

Authors:  P C Appelbaum
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

Review 2.  Pneumococcal resistance to antibiotics.

Authors:  K P Klugman
Journal:  Clin Microbiol Rev       Date:  1990-04       Impact factor: 26.132

3.  Susceptibility of multiply antibiotic-resistant pneumococci to the new quinoline antibiotics, nalidixic acid, coumermycin, and novobiocin.

Authors:  M E Gombert; T M Aulicino
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

4.  Pharmacokinetics and therapeutic efficacy of imipenem, ceftazidime, and ceftriaxone in experimental meningitis due to an ampicillin- and chloramphenicol-resistant strain of Haemophilus influenzae type b.

Authors:  Y Sakata; G H McCracken; M L Thomas; K D Olsen
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

Review 5.  Imipenem/cilastatin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  S P Clissold; P A Todd; D M Campoli-Richards
Journal:  Drugs       Date:  1987-03       Impact factor: 9.546

6.  Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

7.  Antimicrobial therapy of experimental meningitis caused by Streptococcus pneumoniae strains with different susceptibilities to penicillin.

Authors:  G H McCracken; Y Sakata
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

Review 8.  Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.